Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
SPIGEL, David R, BURRIS, Howard A, BASS, J. David, HAINSWORTH, John D, GRECO, F. Anthony, SHIPLEY, Dianna L, FRIEDMAN, Elke K, WATERHOUSE, David M, WHORF, Robert C, MITCHELL, R. Brian, DANIEL, Davey B, ZANGMEISTER, Jeffrey
Published in Journal of clinical oncology (20.06.2011)
Published in Journal of clinical oncology (20.06.2011)
Get full text
Journal Article
Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer
Pritchett, Michael A, Camidge, D Ross, Patel, Manu, Khatri, Jamil, Boniol, Steven, Friedman, Elke K, Khomani, Abderrahim, Dalia, Samir, Baker-Neblett, Katherine, Plagnol, Vincent, Howarth, Karen D, Jones, Gregory R, Rosenfeld, Nitzan, Morris, Clive D, Govindan, Ramaswamy
Published in JCO precision oncology (2019)
Published in JCO precision oncology (2019)
Get more information
Journal Article
Abstract LB-77: A randomized double-blind placebo-controlled phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small cell lung cancer: Correlative analyses
Spigel, David R., Burris, Howard A., Greco, F. Anthony, Shipley, Diana L., Friedman, Elke K., Waterhouse, David M., Whorf, Robert C., Mitchell, R. Brian, Daniel, Davey B., Zangmeister, Jeffery, Hainsworth, John D.
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Get full text
Journal Article